AS-136A is a small molecule developed as part of the NIH Probes effort. AS-136A is a potent measles virus (MeV) RNA-dependent RNA polymerase (RdRp) inhibitor. AS-136A is very stable, decreases virus titer after 24 hours in physiological conditions, and serves as a positive control in MeV inhibitory assays.
Biochem/physiol Actions
AS-136A is a potent measles virus RdRp inhibitor.
AS-136A is a potent measles virus RdRp inhibitor. Measles virus (MV) is a member of the paramyxovirus family. Ribavirin (R9644) is the only drug available for treatment of paramyxoviruses, and it has limited efficacy against MV. A series of small molecules has been developed to inhibit viral RNA-dependent RNA polymerase (RdRp), a protein vital to infection leading to the development of AS-136A, a very potent RdRp inhibitor. AS-136A has high stability and continues to decrease virus titer after 24 hours in physiologic conditions. AS-136A is now used as a positive control in experiments assaying MV inhibition. This compound is a product of the NIH Probes effort, also known as SID 24769845.
Antimicrobial agents and chemotherapy, 53(9), 3860-3870 (2009-06-17)
No effective therapeutic is currently in place for improved case management of severe measles or the rapid control of outbreaks. Through high-throughput screening, we recently identified a novel small-molecule class that potently blocks activity of the measles virus (MeV) RNA-dependent
Journal of medicinal chemistry, 55(9), 4220-4230 (2012-04-07)
The measles virus (MeV), a member of the paramyxovirus family, is an important cause of pediatric morbidity and mortality worldwide. In an effort to provide therapeutic treatments for improved measles management, we previously identified a small, non-nucleoside organic inhibitor of
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.